Alimera Sciences announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence, or NICE, has issued a positive Appraisal Consultation Document, or ACD, on Iluvien for the treatment of pseudophakic patients with chronic diabetic macular edema, or DME, considered insufficiently responsive to available therapies. The ACD recommends a change to the published guidance issued by NICE on January 29, and takes into consideration a simple patient access scheme, or PAS, that was submitted by Alimera for rapid review.